Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American International Group Inc (AIG) vs Mesoblast Limited (MESO) Price & Performance

American International Group IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

American International Group Inc vs Mesoblast Limited — how do they compare? American International Group Inc trades at $77.4 (market cap $40.58B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: American International Group Inc is far larger — about 18.8× Mesoblast Limited's market cap, and American International Group Inc pays a 2.58% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

AIGMESO
Market Cap
$40.58B$2.16B
Sector
FinancialsTechnology
52-Week High
$86.59$20.96
52-Week Low
$71.89$12.88
Enterprise Value
$48.22B$2.17B
Dividend Yield
2.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American International Group Inc

AIG trades at $78.78, down 1.49% on the day, with a neutral technical stance as RSI readings near 42 suggest balanced momentum. The stock shows solid fundamentals with a P/E of 14.38 and recent earnings beats, including Q2 2026 EPS of $2.00 versus $1.92 expected. Revenue stability around $26.8 billion in 2025 and a net income margin of 11.88% reflect disciplined underwriting and expense control, though investment income headwinds persist. Analyst consensus price target is $88.90, implying potential upside, supported by a 39% buy rating among coverage.

Outlook remains cautiously optimistic given earnings consistency and undervaluation relative to peers, but risks include competitive pricing pressure and macroeconomic volatility affecting insurance demand. The dividend yield of approximately 2.5% adds income appeal, yet high beta exposure may lead to amplified swings in broader market downturns, warranting monitoring of Q3 2026 results for sustained growth catalysts.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About American International Group Inc

American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.

Read more on AIG

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO